Nature Communications (Aug 2023)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine

  • Eva Stadler,
  • Mohamed Maiga,
  • Lukas Friedrich,
  • Vandana Thathy,
  • Claudia Demarta-Gatsi,
  • Antoine Dara,
  • Fanta Sogore,
  • Josefine Striepen,
  • Claude Oeuvray,
  • Abdoulaye A. Djimdé,
  • Marcus C. S. Lee,
  • Laurent Dembélé,
  • David A. Fidock,
  • David S. Khoury,
  • Thomas Spangenberg

DOI
https://doi.org/10.1038/s41467-023-40974-8
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 10

Abstract

Read online

Abstract We report an analysis of the propensity of the antimalarial agent cabamiquine, a Plasmodium-specific eukaryotic elongation factor 2 inhibitor, to select for resistant Plasmodium falciparum parasites. Through in vitro studies of laboratory strains and clinical isolates, a humanized mouse model, and volunteer infection studies, we identified resistance-associated mutations at 11 amino acid positions. Of these, six (55%) were present in more than one infection model, indicating translatability across models. Mathematical modelling suggested that resistant mutants were likely pre-existent at the time of drug exposure across studies. Here, we estimated a wide range of frequencies of resistant mutants across the different infection models, much of which can be attributed to stochastic differences resulting from experimental design choices. Structural modelling implicates binding of cabamiquine to a shallow mRNA binding site adjacent to two of the most frequently identified resistance mutations.